Table 4.

Association of genomic gain/loss with overall survival in four independent datasets of DLBCL patients treated with RCHOP or RCHOP-like regimens.

MCR CNA (Aberration Number, Cytoband)	DS-169 (n=70)		DS-124		DS-41		DS-66
	Freq	P-value	Freq	P-value	Freq	P-value	Freq	P-value
A12q13.11-q13.12 (Ab14, 12q13)	11.4%	0.042	3.2%	0.293	31.7%	0.511	21.2%	0.98
A12q14.2-q21.1 (Ab15, 12q15)	14.3%	0.024	4.8%	0.549	26.8%	0.508	22.7%	0.91
A19q13.33-q13.43 (Ab26, 19q13)	12.9%	<0.001	0.8%	ND	9.8%	0.066	9.1%	0.82
D6q11.1-q27 (Ab36, 6q21)	27.1%	0.709	13.7%	0.709	19.5%	0.005	33.3%	0.98
D6q11.1-q27 (Ab37, 6q21)	25.7%	0.83	14.5%	0.604	14.6%	0.002	30.3%	0.82
D8p22-p21.3 (Ab40, 8p21.3)	7.1%	0.437	5.6%	0.023	2.4%	ND	4.5%	0.48
D9p21.3 (Ab42, 9p21.3)	20.0%	0.447	3.2%	0.345	9.8%	0.008	13.6%	0.58
D15q15.1-q21.1 (Ab45, 15q15.2)	8.6%	0.098	8.9%	0.039	19.5%	0.128*	19.7%	0.37
D17p13.3-p11.2 (Ab48, 17p13.1)	10.0%	0.021	12.9%	0.344	24.4%	0.972	18.2%	0.2
D17p13.3-p11.2 (Ab49, 17p13.1)	10.0%	0.021	12.9%	0.344	24.4%	0.972	16.7%	0.13

Freq, Frequency; ND, not done

^*Trending with longer OS